文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA放射性配体治疗在转移性去势抵抗性前列腺癌早期与晚期阶段按既往紫杉烷化疗分组的临床结局

Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy.
PubMed 文献 · J Nucl Med · 2019-01-25

该回顾性研究纳入167例接受177Lu-PSMA放射性配体治疗(177Lu-PRLT)的mCRPC患者,按既往是否接受紫杉烷化疗分为T-pretreated组(83例)和T-naïve组(84例)。T-naïve组中位总生存期(OS)为27.1个月,T-pretreated组为10.7个月;两组PSA缓解率分别为57%和40%,整体安全性良好。

要点

  • T-naïve组中位OS为27.1个月,T-pretreated组为10.7个月。
  • T-naïve组PSA缓解率57%,T-pretreated组40%。
  • 177Lu-PRLT在两组中均显示最小不良反应。

核心结论

  • 177Lu-PRLT在mCRPC中是有前景的治疗,在T-naïve和经重度治疗的患者队列中均观察到令人鼓舞的结局和最小毒性。

主要发现

  • T-pretreated组中位OS为10.7个月,T-naïve组为27.1个月。
  • T-pretreated组中位影像学无进展生存期为6.0个月,T-naïve组为8.8个月。
  • PSA缓解在132例可评估患者中,T-pretreated组62例中25例(40%)见缓解,T-naïve组70例中40例(57%)见缓解。
  • 多变量分析中,T-pretreated组OS较差的显著决定因素为较差体能状态、较低累积给药活度和较低基线血红蛋白;T-naïve组仅较高基线碱性磷酸酶为OS较差的显著决定因素。
  • 177Lu-PRLT整体安全,随访期间两组均见最小不良反应。

临床怎么用

  • 对于mCRPC患者,在紫杉烷化疗前或后阶段均可考虑177Lu-PRLT,但T-pretreated患者预后相对较差。
  • 治疗前应评估体能状态、累积给药活度、基线血红蛋白和碱性磷酸酶以辅助风险分层。

局限性

  • 本研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (177Lu-PRLT) is an emerging treatment in metastatic castration-resistant prostate cancer (mCRPC). This retrospective study evaluates clinical outcomes of 177Lu-PRLT in earlier and later phases of mCRPC grouped by previous taxane chemotherapy. Methods: A retrospective analysis was performed on 167 patients with mCRPC who underwent 177Lu-PRLT between March 2013 and December 2016. Patients were classified as either taxane chemotherapy pretreated (T-pretreated) or naïve (T-naïve) depending on whether they had received taxane-based chemotherapy prior to 177Lu-PRLT. Clinical outcome for T-pretreated and T-naïve patients was assessed by overall survival (OS), radiographic progression-free survival, and prostate-specific antigen (PSA) response rate. Univariate and multivariable analyses were performed for both T-pretreated and T-naïve patients to determine predictors of outcome. Toxicity was categorized by the Common Terminology Criteria for Adverse Events (version 4.03). Results: Of the 167 patients treated with 177Lu-PRLT, 83 were T-pretreated and 84 were T-naïve. At baseline, T-pretreated patients had overall poorer performance status, a higher prevalence of bone metastases, higher PSA levels, lower hemoglobin levels, higher alkaline phosphatase (ALP) levels and had received more additional therapies compared with T-naïve patients. Median OS was 10.7 mo for T-pretreated patients and 27.1 mo for T-naïve patients. Median radiographic progression-free survival was 6.0 mo for T-pretreated patients and 8.8 mo for T-naïve patients. PSA response assessment was evaluable in 132 patients and seen in 25 of 62 (40%) T-pretreated patients and 40 of 70 (57%) T-naïve patients. Significant determinates of inferior OS in multivariable analysis for T-pretreated patients were poorer performance status, lower cumulative administered activity, and lower baseline hemoglobin. Higher baseline alkaline phosphatase was the only significant determinate of inferior OS in multivariable analysis for T-naïve patients. Overall 177Lu-PRLT was safe, with minimal adverse effects evident during follow-up in both T-pretreated and T-naïve patients. Conclusion: 177Lu-PRLT is a promising therapy in mCRPC, with encouraging outcomes and minimal associated toxicity seen in both our T-naïve and heavily pretreated patient cohorts.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Barber TW, Singh A, Kulkarni HR, et al. Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. J Nucl Med. 2019. PMID: 30683770. doi:10.2967/jnumed.118.216820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。